U.S. markets closed
  • S&P 500

    3,363.00
    +27.53 (+0.83%)
     
  • Dow 30

    27,781.70
    +329.04 (+1.20%)
     
  • Nasdaq

    11,167.51
    +82.26 (+0.74%)
     
  • Russell 2000

    1,507.69
    +2.96 (+0.20%)
     
  • Crude Oil

    40.05
    -0.17 (-0.42%)
     
  • Gold

    1,892.90
    -2.60 (-0.14%)
     
  • Silver

    23.44
    -0.05 (-0.23%)
     
  • EUR/USD

    1.1738
    +0.0012 (+0.11%)
     
  • 10-Yr Bond

    0.6770
    +0.0320 (+4.96%)
     
  • GBP/USD

    1.2919
    -0.0002 (-0.02%)
     
  • USD/JPY

    105.4270
    -0.0030 (-0.00%)
     
  • BTC-USD

    10,775.43
    -68.78 (-0.63%)
     
  • CMC Crypto 200

    221.39
    -0.01 (-0.00%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Bellicum to Participate in Two Upcoming Virtual Investor Conferences

Bellicum Pharmaceuticals, Inc.

HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences.

Conference Details:

Wells Fargo 2020 Virtual Healthcare Conference
Date/Time: Wednesday, September 9, 2020 at 12:40 p.m. EDT
Format: Analyst Moderated Discussion

H.C. Wainwright 22nd Annual Global Investment Conference
Date/Time: Tuesday, September 15, 2020 at 2:30 p.m. EDT
Format: Presentation

A live webcast of the analyst moderated discussion session at Wells Fargo and the H.C. Wainwright presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com